Trial Profile
Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- 15 May 2018 Status changed from recruiting to completed.
- 25 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
- 25 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.